WELLESLEY HILLS, Mass., March 19 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTC Bulletin Board: MACM) today announced the appointment of David P. Luci to the position of Chief Financial Officer, effective immediately. Mr. Luci has served as MacroChem's General Counsel and Vice President, Corporate Development since joining the Company in December 2007.
Mr. Luci was formerly the CFO of Bioenvision, Inc. prior to its successful merger transaction with Genzyme Corporation valued at $345 mm, and has over 16 years of experience servicing or working in the finance, accounting and legal functions within the healthcare industry. Bioenvision's primary focus was developing compounds for the treatment of cancer. While Mr. Luci was at Bioenvision, the company raised over $100 million of capital through equity financings, primarily lead by UBS and JP Morgan, and developed and successfully obtained regulatory approval for a compound to treat pediatric acute leukemia in end-stage patients.
Mr. Luci is also a member of the board of directors, audit committee chairman and compensation committee chairman of Access Pharmaceuticals (OTC Bulletin Board: ACCP.OB) of Dallas, Texas, a biopharmaceutical company focused on development of novel therapies for cancer and other indications. Prior to Bioenvision he also served as a senior associate in the corporate department of Paul, Hastings, Janofsky & Walker LLP (New York Office) and senior auditor at Ernst & Young, LLP (New York Office). In 1991, Mr. Luci earned certification in public accounting.
Mr. Luci stated. "Since joining the company, I have been further encouraged by our potential for future success and look forward to working in this expanded role through the coming stages of growth and opportunity for the Company."
Bernard Patriacca, MacroChem's Chief Financial Officer, will be
retiring as planned following the filing of the company's annual report for
the year ended December 31, 2007 which
|SOURCE MacroChem Corporation|
Copyright©2008 PR Newswire.
All rights reserved